TransMedics Group (NASDAQ:TMDX) Director Stephanie Lovell Sells 1,193 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) Director Stephanie Lovell sold 1,193 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total value of $178,496.66. Following the sale, the director owned 2,866 shares of the company’s stock, valued at approximately $428,810.92. This trade represents a 29.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

TransMedics Group Stock Performance

NASDAQ:TMDX traded down $10.27 on Friday, hitting $129.80. The stock had a trading volume of 1,079,448 shares, compared to its average volume of 828,348. The business’s 50-day simple moving average is $135.35 and its two-hundred day simple moving average is $126.90. The stock has a market cap of $4.45 billion, a price-to-earnings ratio of 26.49 and a beta of 1.98. TransMedics Group, Inc. has a 52-week low of $62.23 and a 52-week high of $156.00. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its stake in shares of TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after purchasing an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after buying an additional 868 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the period. Envestnet Asset Management Inc. boosted its holdings in TransMedics Group by 12.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 26,298 shares of the company’s stock worth $3,524,000 after buying an additional 2,933 shares during the period. Finally, Atria Investments Inc purchased a new stake in TransMedics Group in the 2nd quarter worth $213,000. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TMDX has been the subject of a number of research reports. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Needham & Company LLC upped their price objective on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Piper Sandler raised their target price on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, JPMorgan Chase & Co. boosted their price target on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $150.67.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.